Abstract
PURPOSE Understanding how mechanical properties relate to functional changes in glioblastomas may help explain different treatment response between patients. The aim of this study was to map differences in biomechanical and functional properties between tumor and healthy tissue, to assess any relationship between them and to study their spatial distribution.
METHODS Ten patients with glioblastoma and 17 healthy subjects were scanned using MR Elastography, perfusion and diffusion MRI. Stiffness and viscosity measurements G′ and G′′, cerebral blood flow (CBF), apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were measured in patients’ contrast-enhancing tumor, necrosis, edema, and gray and white matter, and in gray and white matter for healthy subjects. A regression analysis was used to predict CBF as a function of ADC, FA, G′ and G′′.
RESULTS Median G′ and G′′ in contrast-enhancing tumor were 13% and 37% lower than in normal-appearing white matter (P<0.01), and 8% and 6% lower in necrosis than in contrast-enhancing tumor, respectively (P<0.05). Tumors showed both inter-patient and intra-patient heterogeneity. Measurements approached values in normal-appearing tissue when moving outward from the tumor core, but abnormal tissue properties were still present in regions of normal-appearing tissue. Using both a linear and a random-forest model, prediction of CBF was improved by adding MRE measurements to the model (P<0.01).
CONCLUSIONS The inclusion of MRE measurements in statistical models helped predict perfusion, with stiffer tissue associated with lower perfusion values.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03951142
Funding Statement
We gratefully acknowledge support from the European Union Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, Research and Innovation Grant Agreements No. 668039-FORCE and Marie Skłodowska-Curie grant agreement (No 844646-GLIOHAB), South-Eastern Norway Regional Health Authority (Grant Agreement No. 2017073 and 2013069), The Research Council of Norway FRIPRO (Grant Agreement No. 261984), the National Institute of Health R21 grant (Grant Agreement No. EB030757), and the German Research Foundation (DFG, SCHR 1542/1-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Norwegiean National Research Ethics Committee and the Oslo University Hospital review board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant Support: We gratefully acknowledge support from the European Union’s Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, Research and Innovation Grant Agreements No. 668039-FORCE and Marie Skłodowska-Curie grant agreement (No 844646-GLIOHAB), South-Eastern Norway Regional Health Authority (Grant Agreement No. 2017073 and 2013069), The Research Council of Norway FRIPRO (Grant Agreement No. 261984), the National Institutes of Health R21 grant (Grant Agreement No. EB030757), and the German Research Foundation (DFG, SCHR 1542/1-1).
Conflict of interest: Nothing to disclose.
Declaration of interest: KEE: NordicNeuroLab AS, Bergen, Norway – Intellectual property rights.
Data Availability
All the data and the associated meta-data generated as a part of this study is publicly available by request through Zenodo (10.5281/zenodo.4926005).
